Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myriad Genetics, Inc. (NASDAQ: MYGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a molecular diagnostic testing and precision medicine company, Myriad Genetics uses these filings to report financial results, material agreements, leadership changes, and other significant events.
Investors can review Form 8-K filings that announce quarterly financial results, furnish earnings press releases, and describe items such as new credit agreements or changes in executive officers. For example, recent 8-K filings have covered results for quarters ended in 2025, entry into a term loan credit facility, and the appointment or departure of senior finance executives. An 8-K/A amendment has also been used to correct a clerical error in previously furnished financial information.
In addition to current reports, Myriad Genetics files annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, risk factor discussions, and segment information for areas such as hereditary cancer testing, tumor profiling, prenatal testing, and pharmacogenomics. Proxy statements and other governance-related documents provide further detail on board structure and executive compensation.
On Stock Titan, these filings are updated as they become available from the SEC’s EDGAR system. AI-powered tools summarize key points, highlight important sections, and help explain complex topics such as non-GAAP financial measures, credit facility covenants, and the implications of executive transitions. Users can also focus on insider and executive-related disclosures within Forms 3, 4, and 5 when those are filed, to better understand equity awards and ownership changes.
This page is intended as a convenient starting point for reviewing Myriad Genetics’ regulatory history and understanding how the company reports its financial condition, strategic agreements, and corporate governance matters over time.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-withholding disposition of company stock. On April 14, 2026, 1,069 shares of Myriad Genetics common stock were withheld by the company at $4.91 per share to cover his tax obligations from previously granted restricted stock units vesting. After this withholding, Verratti directly holds 629,646 shares of Myriad Genetics common stock, indicating that the transaction represents a very small portion of his overall equity position and does not reflect an open-market sale.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-withholding transaction tied to equity compensation. On April 14, 2026, 946 shares of Common Stock were withheld by the company at $4.91 per share to cover tax obligations from previously granted restricted stock units vesting. After this withholding, Muzzey directly holds 326,310 shares of Myriad Genetics common stock.
Myriad Genetics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026. Proposals include electing three Class III directors, ratifying Ernst & Young as auditor, an advisory vote on executive pay, and approving an amended 2012 Employee Stock Purchase Plan plus a new 2026 equity incentive plan.
In 2025, the company generated $824.5 million in revenue, a 2% decline from 2024, and reported a GAAP net loss of $365.9 million, while producing adjusted EBITDA of $38.9 million and adjusted EPS of $0.06. Total test volumes grew 1%, led by 7% growth in hereditary cancer testing and 6% growth in mental health testing.
The “New Myriad” strategy focuses on the Cancer Care Continuum, with launches planned for the Precise MRD platform, an AI‑enabled Prolaris prostate cancer test and the FirstGene prenatal screen in 2026. Management expects annual revenue growth to accelerate to high‑single‑digit to low‑double‑digit percentages over the mid‑ to long‑term while redirecting and investing more than $35 million into commercial capabilities and key R&D programs.
BlackRock, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting ownership of 7,976,163 shares of Myriad Genetics, Inc. Common Stock as of 03/31/2026. The filing shows 7,841,058 shares of sole voting power and 7,976,163 shares of sole dispositive power, representing 8.5% of the class.
The submission is an institutional beneficial‑ownership disclosure that aggregates holdings of reporting business units of BlackRock, Inc. and is signed by a Managing Director on 04/07/2026.
Myriad Genetics Inc ownership disclosure: The Vanguard Group filed Amendment No. 14 to its Schedule 13G/A stating it beneficially owns 0 shares of Myriad Genetics common stock, representing 0% of the class. The filing explains an internal realignment and separate reporting by certain Vanguard subsidiaries.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-related share withholding. On March 22, 2026, 2,019 shares of Myriad Genetics common stock were withheld by the company at $4.58 per share to cover tax obligations from vesting restricted stock units.
These shares were not sold in the open market but delivered back to the issuer to satisfy taxes. After this tax-withholding disposition, Muzzey directly holds 327,256 shares of Myriad Genetics common stock, indicating the transaction affects only a small portion of his overall equity position.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-related share withholding. On March 22, 2026, 2,055 shares of Common Stock were disposed of at $4.58 per share to satisfy tax obligations tied to vesting restricted stock units. The number of shares withheld was based on the March 20, 2026 closing price. After this withholding, Verratti directly owns 630,715 shares of Myriad Genetics Common Stock.
MYRIAD GENETICS INC Chief Financial Officer Benjamin Richard Wheeler had 549 shares of Common Stock withheld by the company to cover tax obligations tied to restricted stock unit vesting. The withheld shares were valued at $4.58 per share, based on the closing price on March 20, 2026.
These shares were not sold in the open market but retained by the issuer to satisfy tax withholding requirements. After this tax-withholding disposition, Wheeler directly holds 298,509 shares of Myriad Genetics common stock.
MYRIAD GENETICS INC Chief Technology Officer Kevin Richard Haas reported share dispositions that were entirely for tax withholding. Over March 13–15, 2026, a total of 22,310 shares of Common Stock were withheld by the company to satisfy tax obligations from vesting restricted and performance-based stock units.
These F-code transactions are not open-market sales and do not reflect discretionary selling activity. After these tax-withholding events, Haas continues to hold 180,022 shares of Common Stock directly.